ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS
Sign Up to like & getrecommendations! Published in 2017 at "Neuro-oncology"
DOI: 10.1093/neuonc/nox168.123
Abstract: BACKGROUND PF-06840003 is a highly selective and active IDO1 inhibitor, presumed to cross the blood brain barrier. IDO1, produced by cancer or immune cells, by affecting tryptophan catabolism, producing immunosuppressive metabolites such as kynurenine, inhibits… read more here.
Keywords: ido1; ido1 inhibitor; atim phase; study 06840003 ... See more keywords
Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-ct116
Abstract: Background: IDO1 is highly expressed in multiple cancers and may be an immunosuppressive mechanism for tumor escape via its production of metabolites that inhibit T-cell function. Nivo, a mAb that targets PD-1, causes IDO1 upregulation,… read more here.
Keywords: ido1; combination; bms 986205; trial ... See more keywords
Abstract 5555: Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-5555
Abstract: Indoleamine-2,3-dioxygenase (IDO1) is well-recognized as an important target for immunotherapeutic intervention. Growing interests on this target have been demonstrated by the recent expansion of enthusiasms to inhibit the Trp-to-Kyn pathway as a means to control… read more here.
Keywords: potent selective; inhibitor; ido1 inhibitor; 016 highly ... See more keywords
Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3033
Abstract: 3033Background: Melanoma metastases limit infiltration and function of antitumor T cells in part by immunosuppression with IDO1. INCB024360 (epacadostat) is an IDO1 inhibitor that normalizes serum ... read more here.
Keywords: melanoma; ido1; ido1 inhibitor; pilot trial ... See more keywords
Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medicinal Chemistry"
DOI: 10.2210/pdb6kof/pdb
Abstract: Indoleamine 2,3-dioxygenase (IDO1) inhibitors are speculated to be useful in cancer immunotherapy, but a phase III clinical trial of the most advanced IDO1 inhibitor, epacadostat, did not meet its primary end point and was abandoned.… read more here.
Keywords: indoleamine dioxygenase; aromatic interactions; sulfur aromatic; unique sulfur ... See more keywords